Skip to main content
. 2013 Jul 11;8(7):e67296. doi: 10.1371/journal.pone.0067296

Figure 6. Pravastatin induced reduction in cholesterol secretion of stage 3B HLCs derived from iPSCs.

Figure 6

(A) Suppression of cholesterol secretion by treatment of HLCs with pravastatin at 10 μM for 48 hours, as assayed by quantitative fluorometric assessment for cholesterol in cell-fee conditioned medium. T-tests on triplicate values from treated and untreated cells were used to generate p-values. (B) Analysis of HMGCR transcriptional regulation by pravastatin (for cell-type nomenclature see Fig. 3A legend). Also shown is the HMGCR mRNA level from a 2 year old female liver sample. Scales for the liver and HLC samples are identical. (C) Analysis of HNF4α and CYP2E1 transcriptional regulation by pravastatin (for cell-type nomenclature see Fig. 3A legend). Error bars represent the standard error of the mean.